-
Saints Sages Surgical Secures Series B Funding to Advance Energy-Based Devices
•
Shanghai-based Saints Sages Surgical Co., Ltd, a leading developer of high-value minimally invasive surgical products, has successfully raised an undisclosed amount in its Series B financing round. The round was led by Qiming Venture Partners, a returning investor, and the funds will be allocated to the research and development of…
-
Hainan Huluwa Pharmaceutical Gets NMPA Approval for Generic Briviact Clinical Study
•
China-based Hainan Huluwa Pharmaceutical Group Co., Ltd (SHA: 605199) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its generic version of UCB Pharma’s Briviact (brivaracetam). The Category III injectable is in development for use as an adjuvant treatment…
-
CSPC Pharmaceutical Group Partners with Insilico and XtalPi for AI-Driven Drug R&D
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced strategic partnership agreements with Insilico Medicine Ltd and Shenzhen XtalPi (QuantumPharm, HKG: 2228). These collaborations will integrate artificial intelligence (AI) into the field of innovative drug research and development. Under the agreements, CSPC will utilize its drug R&D expertise alongside the…
-
Luye Pharma Group Submits Market Approval Filing for Lurbinectedin in Metastatic SCLC in Macau
•
China-based Luye Pharma Group (HKG: 2186) has announced that a market approval filing has been submitted to Macau’s medical products administration bureau for the company’s drug lurbinectedin (LY01017). The targeted indication is for the treatment of metastatic small-cell lung cancer (SCLC) in patients who experience tumor progression during or after…
-
magAssist Receives FDA Breakthrough Device Designation for NyokAssist VAD
•
magAssist, a firm based in Suzhou, China, has announced that it has received breakthrough device designation from the US Food and Drug Administration (FDA) for its artificial heart product, the NyokAssist interventional ventricular assist device (VAD). The company highlights that this designation recognizes the cutting-edge design features of its innovative…
-
Auzone Biological Technology Gets FDA Approval for Edaravone Oral Preparations in ALS
•
Suzhou Auzone Biological Technology Co., Ltd. has received approval from the US Food and Drug Administration (FDA) to initiate a pivotal clinical study for its edaravone oral preparations in the treatment of amyotrophic lateral sclerosis (ALS). The Chinese company, which has a wholly owned subsidiary in Australia, is planning to…
-
RemeGen Ltd Reports 20.56% YOY Revenue Growth in H1 2023 Financial Results
•
China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has released its financial report for the first half of 2023, recording revenues of RMB 422 million, an increase of 20.56% year-on-year (YOY). The company has also ramped up its research and development (R&D) costs to RMB 540 million, marking a 20.19% YOY…
-
Gilead’s Magrolimab Phase III Trial for AML Faces Partial Hold by FDA
•
Gilead (NASDAQ: GILD) has announced that the US Food and Drug Administration (FDA) has imposed a partial hold on recruitment for a Phase III trial of its investigational anti-CD47 biologic, magrolimab, in acute myeloid leukemia (AML). The company has not disclosed the reason behind the FDA’s decision but has indicated…